Literature DB >> 15990815

Long-term results of photodynamic therapy with 5-aminolevulinic acid for superficial Barrett's cancer and high-grade intraepithelial neoplasia.

Oliver Pech1, Liebwin Gossner, Andrea May, Thomas Rabenstein, Michael Vieth, Manfred Stolte, Manfred Berres, Christian Ell.   

Abstract

BACKGROUND: Photodynamic therapy (PDT) with 5-aminolevulinic acid (ALA) has proven to be safe and effective in patients with early neoplasia in Barrett's esophagus. However, long-term results in patients with high-grade intraepithelial neoplasia (HGIN) or with early cancer are still lacking.
METHODS: The aim of the study was to evaluate the efficacy of ALA-PDT and the survival of patients with early Barrett's neoplasia. ALA-PDT was carried out in 66 patients. Protoporphyrin IX induced by oral administration of ALA (60 mg/kg body weight orally applied 4-6 hours before PDT) was used as the photosensitizer. Acid suppression was maintained in all patients.
RESULTS: Between September 1996 and September 2002, 667 patients with early neoplasia in Barrett's esophagus were referred for local endoscopic therapy. A total of 558 patients fulfilled the criteria for local endoscopic therapy, and 66 patients (mean [standard deviation] age 61.4 [10.2] years) with HGIN (group A; n = 35) and early adenocarcinoma (group B; n = 31) were treated by PDT. A total of 82 ALA-PDT were performed. A total of 34 of the 35 patients in group A (97%) and all patients in group B (100%) achieved a complete response during a median follow-up period of 37 months (interquartile range 23-55) (not significant). One local recurrence was observed in group A and 10 in group B (p < 0.005). Seven patients died during follow-up; but, all deaths were not tumor related. No major complications were observed. Disease-free survival in patients with HGIN was 89%, and, in patients with mucosal cancer, it was 68%. The calculated 5-year survival was 97% in group A and 80% in group B, but there occurred no death related to Barrett's neoplasia.
CONCLUSIONS: The excellent long-term results of PDT with ALA in patients with HGIN or mucosal cancer might offer PDT with ALA as an alternative to surgical esophagectomy and endoscopic resection, especially in cases with multifocal Barrett's neoplasia.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15990815     DOI: 10.1016/s0016-5107(05)00333-0

Source DB:  PubMed          Journal:  Gastrointest Endosc        ISSN: 0016-5107            Impact factor:   9.427


  32 in total

Review 1.  Endoscopic management of Barrett's esophagus: advances in endoscopic techniques.

Authors:  Ali Azarm; Ismet Lukolic; Meenal Shukla; Ronald Concha-Parra; Frank Gress
Journal:  Dig Dis Sci       Date:  2012-07-04       Impact factor: 3.199

Review 2.  Guidelines for surgical treatment of gastroesophageal reflux disease.

Authors:  Dimitrios Stefanidis; William W Hope; Geoffrey P Kohn; Patrick R Reardon; William S Richardson; Robert D Fanelli
Journal:  Surg Endosc       Date:  2010-08-20       Impact factor: 4.584

3.  Barrett's esophagus and the increasing role of endoluminal therapy.

Authors:  Michael S Smith; Charles J Lightdale
Journal:  Therap Adv Gastroenterol       Date:  2008-09       Impact factor: 4.409

4.  Endoscopic resection techniques and ablative therapies for Barrett's neoplasia.

Authors:  Jacobo Ortiz-Fernández-Sordo; Adolfo Parra-Blanco; Alejandro García-Varona; María Rodríguez-Peláez; Erika Madrigal-Hoyos; Irving Waxman; Luis Rodrigo
Journal:  World J Gastrointest Endosc       Date:  2011-09-16

Review 5.  Endoscopic options for treatment of dysplasia in Barrett's esophagus.

Authors:  R Brooks Vance; Kerry B Dunbar
Journal:  World J Gastrointest Endosc       Date:  2015-12-25

6.  Diagnosis and management of Barrett's esophagus for the endoscopist.

Authors:  Sagar S Garud; Steven Keilin; Qiang Cai; Field F Willingham
Journal:  Therap Adv Gastroenterol       Date:  2010-07       Impact factor: 4.409

7.  Long-term survival following endoscopic and surgical treatment of high-grade dysplasia in Barrett's esophagus.

Authors:  Ganapathy A Prasad; Kenneth K Wang; Navtej S Buttar; Louis-Michel Wongkeesong; Kausilia K Krishnadath; Francis C Nichols; Lori S Lutzke; Lynn S Borkenhagen
Journal:  Gastroenterology       Date:  2007-02-07       Impact factor: 22.682

8.  Utility of biomarkers in prediction of response to ablative therapy in Barrett's esophagus.

Authors:  Ganapathy A Prasad; Kenneth K Wang; Kevin C Halling; Navtej S Buttar; Louis-Michel Wongkeesong; Alan R Zinsmeister; Shannon M Brankley; Emily G Barr Fritcher; Wytske M Westra; Kausilia K Krishnadath; Lori S Lutzke; Lynn S Borkenhagen
Journal:  Gastroenterology       Date:  2008-05-07       Impact factor: 22.682

Review 9.  Endotherapy for Barrett's esophagus with high-grade dysplasia and intramucosal carcinoma.

Authors:  Drew B Schembre
Journal:  J Gastrointest Surg       Date:  2009-03-26       Impact factor: 3.452

Review 10.  History, molecular mechanisms, and endoscopic treatment of Barrett's esophagus.

Authors:  Stuart Jon Spechler; Rebecca C Fitzgerald; Ganapathy A Prasad; Kenneth K Wang
Journal:  Gastroenterology       Date:  2010-01-18       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.